IQVIA(US:IQV)2021-04-22 17:43Q1 2021 Financial Performance - Revenue increased to $3409 million, a 23.8% increase AFx (actual currency) and 21.4% increase CFx (constant currency) compared to $2754 million in Q1 2020 [8] - Adjusted EBITDA reached $744 million, up 32.4% AFx from $562 million in Q1 2020 [8] - Adjusted Diluted EPS rose to $2.18, a 45.3% increase AFx from $1.50 in Q1 2020 [8] - Net income was $212 million, significantly higher than the $82 million reported in Q1 2020 [9] Segment Performance - Technology & Analytics Solutions revenue grew to $1348 million, a 20.7% increase AFx and 17.1% increase CFx compared to $1117 million in Q1 2020 [8] - Research & Development Solutions revenue increased to $1868 million, a 29.6% increase AFx and 28.1% increase CFx compared to $1441 million in Q1 2020 [8] - Contract Sales & Medical Solutions revenue decreased slightly to $193 million, a (1.5)% decrease AFx and (4.1)% decrease CFx compared to $196 million in Q1 2020 [8] Balance Sheet and Cash Flow - Cash and cash equivalents stood at $2305 million [12] - Gross debt amounted to $12236 million, with net debt at $9931 million [12] - Free cash flow was $718 million [12] Full-Year 2021 Guidance - Revenue is projected to be between $13200 million and $13500 million, representing a 16.2% - 18.8% increase [13] - Adjusted EBITDA is expected to be between $2900 million and $2965 million, a 21.6% - 24.4% increase [13] - Adjusted Diluted EPS is forecasted to be between $8.50 and $8.75, a 32.4% - 36.3% increase [13]